LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Начало・Списък с акции・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

7.47 3.03

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.47

Максимум

7.47

Ключови измерители
By Trading Economics
Приходи	7.8M 13M
Продажби	-4M 159M
Марж на печалбата	8.092
Служители	580
EBITDA	3.7M 32M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+188.59% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	138M 1.7B
Предишно отваряне	4.44
Предишно затваряне	7.47

Настроения в новините

By Acuity

67%

33%

314 / 351 Класиране в Healthcare

BioCryst Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.02.2026 г., 17:37 ч. UTC

Придобивния, сливания и поглъщания

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

21.02.2026 г., 14:31 ч. UTC

Придобивния, сливания и поглъщания

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21.02.2026 г., 05:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

20.02.2026 г., 23:12 ч. UTC

Придобивния, сливания и поглъщания

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20.02.2026 г., 22:12 ч. UTC

Печалби

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

20.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.02.2026 г., 21:23 ч. UTC

Печалби

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20.02.2026 г., 21:20 ч. UTC

Пазарно говорене

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20.02.2026 г., 21:01 ч. UTC

Придобивния, сливания и поглъщания

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20.02.2026 г., 20:38 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

20.02.2026 г., 20:17 ч. UTC

Пазарно говорене

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

20.02.2026 г., 20:11 ч. UTC

Пазарно говорене

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

20.02.2026 г., 19:59 ч. UTC

Пазарно говорене

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

20.02.2026 г., 19:58 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

20.02.2026 г., 19:49 ч. UTC

Пазарно говорене

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

20.02.2026 г., 19:09 ч. UTC

Пазарно говорене

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

20.02.2026 г., 19:00 ч. UTC

Пазарно говорене

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

20.02.2026 г., 18:28 ч. UTC

Пазарно говорене

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

20.02.2026 г., 18:20 ч. UTC

Пазарно говорене

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

20.02.2026 г., 18:05 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

20.02.2026 г., 18:04 ч. UTC

Пазарно говорене

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

20.02.2026 г., 17:38 ч. UTC

Пазарно говорене

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

20.02.2026 г., 17:24 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.02.2026 г., 17:24 ч. UTC

Пазарно говорене

Correction to Treasury Yields Fall Market Talk

20.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

20.02.2026 г., 16:53 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

20.02.2026 г., 16:53 ч. UTC

Пазарно говорене

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

20.02.2026 г., 16:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.02.2026 г., 16:45 ч. UTC

Пазарно говорене

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

BioCryst Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

188.59% нагоре

12-месечна прогноза

Среден 21.5 USD 188.59%

Висок 32 USD

Нисък 13 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за BioCryst Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на BioCryst Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

314 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.